Technical Analysis for PLRX - Pliant Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 25.17 -2.29% -0.59
PLRX closed down 2.29 percent on Friday, July 10, 2020, on 29 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong N/A N/A Down
Historical PLRX trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New Uptrend Bullish -2.29%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.
Medicine Medical Specialties Hepatitis Hepatology Idiopathic Pulmonary Fibrosis Non Alcoholic Fatty Liver Disease Fibrosis Liver Fibrosis Primary Sclerosing Cholangitis Muscular Dystrophies

Is PLRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 35.63
52 Week Low 21.05
Average Volume 212,236
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 28.24
10-Day Moving Average 29.16
Average True Range 2.27
ADX 49.56
+DI 18.32
-DI 21.02
Chandelier Exit (Long, 3 ATRs ) 28.82
Chandelier Exit (Short, 3 ATRs ) 28.81
Upper Bollinger Band 34.07
Lower Bollinger Band 22.41
Percent B (%b) 0.24
BandWidth 41.31
MACD Line 1.07
MACD Signal Line 1.79
MACD Histogram -0.724
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.66
Resistance 3 (R3) 26.69 26.22 26.41
Resistance 2 (R2) 26.22 25.84 26.20 26.33
Resistance 1 (R1) 25.69 25.60 25.46 25.67 26.25
Pivot Point 25.22 25.22 25.10 25.21 25.22
Support 1 (S1) 24.70 24.84 24.46 24.67 24.09
Support 2 (S2) 24.23 24.61 24.21 24.01
Support 3 (S3) 23.70 24.23 23.93
Support 4 (S4) 23.68